CA3090859C - MODIFIED ADENOVIRUS - Google Patents
MODIFIED ADENOVIRUSInfo
- Publication number
- CA3090859C CA3090859C CA3090859A CA3090859A CA3090859C CA 3090859 C CA3090859 C CA 3090859C CA 3090859 A CA3090859 A CA 3090859A CA 3090859 A CA3090859 A CA 3090859A CA 3090859 C CA3090859 C CA 3090859C
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- mutation
- modified
- adenovirus
- adenovirus according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10345—Special targeting system for viral vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1802539.5A GB201802539D0 (en) | 2018-02-16 | 2018-02-16 | Modified adenoviruses |
| GB1802539.5 | 2018-02-16 | ||
| PCT/GB2019/050380 WO2019158914A1 (en) | 2018-02-16 | 2019-02-13 | Modified adenoviruses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3090859A1 CA3090859A1 (en) | 2019-08-22 |
| CA3090859C true CA3090859C (en) | 2025-04-01 |
Family
ID=61783770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3090859A Active CA3090859C (en) | 2018-02-16 | 2019-02-13 | MODIFIED ADENOVIRUS |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12318418B2 (enExample) |
| EP (1) | EP3737403B1 (enExample) |
| JP (3) | JP7862138B2 (enExample) |
| KR (1) | KR102687425B1 (enExample) |
| CN (2) | CN118834841A (enExample) |
| AU (1) | AU2019220607B2 (enExample) |
| CA (1) | CA3090859C (enExample) |
| DK (1) | DK3737403T5 (enExample) |
| ES (1) | ES2968387T3 (enExample) |
| FI (1) | FI3737403T3 (enExample) |
| GB (1) | GB201802539D0 (enExample) |
| IL (1) | IL276535B2 (enExample) |
| PL (1) | PL3737403T3 (enExample) |
| PT (1) | PT3737403T (enExample) |
| SG (1) | SG11202007470QA (enExample) |
| WO (1) | WO2019158914A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| ES2899913T3 (es) | 2014-09-24 | 2022-03-15 | Salk Inst For Biological Studi | Virus tumorales oncolíticos y métodos de uso |
| EP3390645B1 (en) | 2016-02-23 | 2022-09-14 | Salk Institute for Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| AU2017375633C1 (en) | 2016-12-12 | 2023-04-27 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| GB201802539D0 (en) * | 2018-02-16 | 2018-04-04 | Univ College Cardiff Consultants Ltd | Modified adenoviruses |
| BR112020019942A2 (pt) | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
| EP3812465A1 (en) * | 2019-10-21 | 2021-04-28 | Universität Ulm | Adenovirus comprising a modified adenovirus hexon protein |
| WO2021205364A1 (en) * | 2020-04-07 | 2021-10-14 | Shenzhen Hua Yao Kang Ming Biopharmaceutical Co., Ltd. | Engineered oncolytic adenovirus |
| CA3209730A1 (en) * | 2021-03-29 | 2022-10-06 | Alan Parker | Modified adenovirus |
| GB202214580D0 (en) | 2022-10-04 | 2022-11-16 | Univ College Cardiff Consultants Ltd | Adenoviral vector therapy |
| GB202314435D0 (en) | 2023-09-20 | 2023-11-01 | Univ College Cardiff Consultants Ltd | Modified adenovirus |
| CN121203037B (zh) * | 2025-09-26 | 2026-05-12 | 北京因诺惟康医药科技有限公司 | 基于整合素改造的特异性靶向心脏及肌肉的aav9优势突变体 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1516055A4 (en) | 2002-01-24 | 2007-08-08 | Scripps Research Inst | FIBER OPERATING MODIFICATIONS FOR EFFICIENT TARGETS |
| CA2519680A1 (en) * | 2003-03-28 | 2004-11-18 | The Scripps Research Institute | Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes |
| GB0520068D0 (en) * | 2005-10-03 | 2005-11-09 | Cancer Res Technology | av peptide ligand |
| ES2367227T3 (es) * | 2007-03-14 | 2011-10-31 | Institut Catala D'oncologia | Adenovirus con mutaciones en el dominio de retención en el retículo endoplasmático de la proteína e3-19k y su utilización en el tratamiento del cáncer. |
| US20110104788A1 (en) * | 2008-02-07 | 2011-05-05 | Andrew Baker | Modulation of Adenoviral Tropism |
| AU2011306846B2 (en) * | 2010-09-24 | 2015-05-14 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors and methods and uses related thereto |
| EP3247807B1 (en) | 2015-01-20 | 2020-12-16 | Adcure Biotechnologies, LLC. | Detargeted adenovirus variants and related methods |
| GB201802539D0 (en) * | 2018-02-16 | 2018-04-04 | Univ College Cardiff Consultants Ltd | Modified adenoviruses |
-
2018
- 2018-02-16 GB GBGB1802539.5A patent/GB201802539D0/en not_active Ceased
-
2019
- 2019-02-13 JP JP2020543282A patent/JP7862138B2/ja active Active
- 2019-02-13 FI FIEP19711157.8T patent/FI3737403T3/fi active
- 2019-02-13 CN CN202410794965.6A patent/CN118834841A/zh active Pending
- 2019-02-13 KR KR1020207026679A patent/KR102687425B1/ko active Active
- 2019-02-13 PT PT197111578T patent/PT3737403T/pt unknown
- 2019-02-13 PL PL19711157.8T patent/PL3737403T3/pl unknown
- 2019-02-13 ES ES19711157T patent/ES2968387T3/es active Active
- 2019-02-13 EP EP19711157.8A patent/EP3737403B1/en active Active
- 2019-02-13 US US16/970,003 patent/US12318418B2/en active Active
- 2019-02-13 CA CA3090859A patent/CA3090859C/en active Active
- 2019-02-13 SG SG11202007470QA patent/SG11202007470QA/en unknown
- 2019-02-13 CN CN201980026226.XA patent/CN112020368B/zh active Active
- 2019-02-13 IL IL276535A patent/IL276535B2/en unknown
- 2019-02-13 WO PCT/GB2019/050380 patent/WO2019158914A1/en not_active Ceased
- 2019-02-13 AU AU2019220607A patent/AU2019220607B2/en active Active
- 2019-02-13 DK DK19711157.8T patent/DK3737403T5/da active
-
2023
- 2023-11-10 JP JP2023191972A patent/JP2024020345A/ja active Pending
-
2025
- 2025-02-19 JP JP2025025180A patent/JP2025081522A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2968387T3 (es) | 2024-05-09 |
| IL276535B1 (en) | 2025-03-01 |
| KR102687425B1 (ko) | 2024-07-22 |
| IL276535B2 (en) | 2025-07-01 |
| JP2024020345A (ja) | 2024-02-14 |
| JP2025081522A (ja) | 2025-05-27 |
| IL276535A (en) | 2020-09-30 |
| PL3737403T3 (pl) | 2024-03-18 |
| PT3737403T (pt) | 2024-01-24 |
| WO2019158914A1 (en) | 2019-08-22 |
| DK3737403T5 (da) | 2024-08-26 |
| JP2021513843A (ja) | 2021-06-03 |
| FI3737403T3 (fi) | 2024-01-17 |
| SG11202007470QA (en) | 2020-09-29 |
| CA3090859A1 (en) | 2019-08-22 |
| EP3737403A1 (en) | 2020-11-18 |
| JP7862138B2 (ja) | 2026-05-19 |
| CN112020368A (zh) | 2020-12-01 |
| AU2019220607A1 (en) | 2020-09-17 |
| CN118834841A (zh) | 2024-10-25 |
| EP3737403B1 (en) | 2024-01-03 |
| CN112020368B (zh) | 2024-07-12 |
| US20210100855A1 (en) | 2021-04-08 |
| KR20200122346A (ko) | 2020-10-27 |
| DK3737403T3 (da) | 2024-01-22 |
| US12318418B2 (en) | 2025-06-03 |
| AU2019220607B2 (en) | 2024-02-15 |
| GB201802539D0 (en) | 2018-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3737403B1 (en) | Modified adenoviruses | |
| JP7066812B2 (ja) | 癌を治療するための治療用組成物及び使用方法 | |
| EP2486137B1 (en) | Replication-competent ad11p based viral vectors | |
| JP5284780B2 (ja) | 癌の治療のための単純ヘルペスウイルス２型変異体の使用 | |
| JP5075839B2 (ja) | 癌の処置のための腫瘍崩壊性アデノウイルス | |
| JPH08507076A (ja) | 新形成の治療及び予防のための細胞障害ウイルス | |
| PT2293804E (pt) | Vírus herpes simplex (hsv) com tropismo modificado, suas utilizações e processo de preparação | |
| JP7303369B2 (ja) | 腫瘍溶解性ウイルス、その使用、およびがんを治療する医薬品 | |
| JP5186693B2 (ja) | 低酸素状態にある細胞で増殖するウイルスまたは遺伝子を発現するウイルスベクター | |
| HK40030481B (en) | Modified adenoviruses | |
| HK40030481A (en) | Modified adenoviruses | |
| JP7508109B2 (ja) | ヒト３５型アデノウイルスを基盤とした腫瘍溶解性ウイルス | |
| US20240180982A1 (en) | Modified adenovirus | |
| WO2024074825A1 (en) | Adenoviral vector therapy | |
| EP3997106A1 (en) | Oncolytic non-human adenoviruses and uses thereof | |
| CA2627638A1 (en) | Conditionally replicating viruses and methods for cancer virotherapy | |
| AU2024345517A1 (en) | Modified adenovirus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231226 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-4-6-B10-B12-B302 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - CONDITIONS FOR GRANT DETERMINED NOT COMPLIANT Effective date: 20240702 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241220 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241220 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241220 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT Effective date: 20250303 |
|
| Q17 | Modified document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED Effective date: 20250326 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE Effective date: 20250401 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250430 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260204 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260204 |